MULTIMODAL SEQUENCING IDENTIFIES SYNERGISTIC MECHANISMS DRIVING RESISTANCE TO NEOADJUVANT NIVOLUMAB TREATMENT IN HCC (AASLD 2026) - Oct 6, 2026 - Abstract #4246; Pres time: Nov 8, 2026; 01:00 PM - 02:00 PM; Location: Convention Center: Poster Hall, Hall DE; "Collectively, these findings provide a comprehensive mechanistic framework for anti-PD1 resistance, unveiling actionable biomarkers and a translational vulnerability to enhance precision therapeutics in HCC."
Clinical • IO biomarker • Hepatocellular Cancer • Metabolic Disorders • Solid Tumor • CD8
|
|
Irene Ng1; Fanhong Zeng2; Jiax Guo1; Zheng Zeng1; Vanilla Zhang2; Daniel Ho2
|